becton dickinson and co
(BDX:New York Consolidated)
becton dickinson and co (BDX) Snapshot
|
Open
$99.55
|
Previous Close
$100.02
|
|
|
Day High
$100.57
|
Day Low
$99.24
|
|
|
52 Week High
05/22/13 - $102.73
|
52 Week Low
06/4/12 - $71.56
|
|
|
Market Cap
19.5B
|
Average Volume 10 Days
998.0K
|
|
|
EPS TTM
$5.72
|
Shares Outstanding
194.3M
|
|
|
EX-Date
06/5/13
|
P/E TM
17.5x
|
|
|
Dividend
$1.98
|
Dividend Yield
1.89%
|
becton dickinson and co (BDX) Latest News
becton dickinson and co (BDX) Related Businessweek News
No Related Businessweek News Foundbecton dickinson and co (BDX) Details
Becton, Dickinson and Company, a medical technology company, develops, manufactures, and sells medical devices, instrument systems, and reagents worldwide. The company’s BD Medical segment produces medical devices that are used in various healthcare settings. This segment’s products include needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; syringes and pen needles used in treatment of diabetes; prefillable drug delivery systems; anesthesia needles and trays; sharps disposal containers; and closed-system transfer devices. Its BD Diagnostics segment provides products for the collection and transport of diagnostics specimens; and instrument systems and reagents to detect various infectious diseases, healthcare-associated infections, and cancers. This segment’s products comprise integrated systems for specimen collection; safety-engineered blood collection products and systems; automated blood culturing systems; molecular testing systems; microorganism identification and drug susceptibility systems; liquid-based cytology systems; rapid diagnostic assays; microbiology laboratory automation; and plated media. The company’s BD Biosciences segment offers research and clinical tools that facilitate the study of cells and their components. This segment’s products include fluorescence-activated cell sorters and analyzers; monoclonal antibodies and kits for performing cell analysis; reagent systems for life science research; cell imaging systems; laboratory products for tissue culture and fluid handling; diagnostic assays; and cell culture media supplements for biopharmaceutical manufacturing. The company markets its products through independent distribution channels and sales representatives to healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry, and the general public. Becton, Dickinson and Company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.
becton dickinson and co (BDX) Top Compensated Officers
becton dickinson and co (BDX) Key Developments
The Board of Directors of Becton, Dickinson and Company has declared a quarterly dividend of 49.5 cents per common share, payable on June 28, 2013 to holders of record on June 7, 2013. The indicated annual dividend rate is $1.98 per share.
Becton, Dickinson and Company announced unaudited consolidated earnings results for the second quarter and six months ended March 31, 2013. For the quarter, the company reported revenues of $2,000,375,000 compared to $1,928,961,000 a year ago. Operating income was $381,132,000 compared to $383,330,000 a year ago. Income from continuing operations before income taxes was $360,471,000 compared to $369,525,000 a year ago. Income from continuing operations was $276,120,000 or $1.39 per diluted share compared to $275,124,000 or $1.31 per diluted share a year ago. Net income was $275,637,000 or $1.39 per diluted share compared to $291,033,000 or $1.39 per diluted share a year ago. For the six months, the company reported revenues of $3,900,567,000 compared to $3,760,681,000 a year ago. Operating income was $773,221,000 compared to $720,087,000 a year ago. Income from continuing operations before income taxes was $726,167,000 compared to $691,967,000 a year ago. Income from continuing operations was $546,370,000 or $2.74 per diluted share compared to $523,669,000 or $2.45 per diluted share a year ago. Net income was $901,073,000 or $4.53 per diluted share compared to $554,019,000 or $2.59 per diluted share a year ago. The company is raised its earnings guidance for the full year 2013 on revenues and earnings per share growth. On a currency-neutral basis, revenue growth is expected to be between 4.5% and 5.0%, or an increase of 50 basis points. Reported revenue growth guidance remains consistent with the company's previously guided range of 3.5% to 4.0%. Reported diluted earnings per share from continuing operations for fiscal year 2013 are expected to be between $5.72 and $5.75, or an increase of $0.03 from the previous guidance range. This represents growth of 6.5% to 7.0% over 2012 adjusted diluted earnings per share of $5.37, which excludes the pension settlement charge in fiscal year 2012. On a currency-neutral basis, earnings per share are expected to increase 100 basis points to 8.5% to 9.0%. After adjusting for the impact of the medical device tax and foreign currency, adjusted diluted earnings per share are expected to grow 11.0% to 11.5%.
Becton, Dickinson and Company, Q2 2013 Earnings Call, May 02, 2013
| Recently Viewed | |||
| BDX:US | $100.43 USD | +0.41 | |
| Company | Last | Change |
| Agilent Technologies Inc | $45.81 USD | -0.43 |
| Boston Scientific Corp | $9.15 USD | +0.015 |
| Corning Inc | $15.76 USD | -0.045 |
| Stryker Corp | $67.43 USD | -0.27 |
| WW Grainger Inc | $259.19 USD | -0.73 |
| View Industry Companies | ||
Industry Analysis
BDX
Industry Average
| Valuation | BDX | Industry Range |
| Price/Earnings | 18.0x |
|
| Price/Sales | 2.5x |
|
| Price/Book | 4.3x |
|
| Price/Cash Flow | 12.9x |
|
| TEV/Sales | 1.7x |
|
Post a JobJobs
- Sandy, UT | Becton DickinsonPosted: May 23
- San Jose, CA | Becton DickinsonPosted: May 22
- San Jose, CA | Becton DickinsonPosted: May 21
- Wilson, NC | Becton DickinsonPosted: May 22
Sponsored Financial Commentaries
Sponsored Links
To contact BECTON DICKINSON AND CO, please visit www.bd.com. Company data is provided by Capital IQ. Please use this form to report any data issues.
Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.







